Get started
HALOZYME THERAPEUTICS INCHALOZYME THERAPEUTICS INCHALOZYME THERAPEUTICS INC

HALOZYME THERAPEUTICS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Bonds

1HALO chart


Full chart

1HALO upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.70 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
17.60
Basic EPS (TTM)
3.38 EUR
Net income (FY)
‪428.98 M‬ EUR
Revenue (FY)
‪980.78 M‬ EUR
Shares float
‪122.23 M‬
Beta (1Y)
0.83

Employees


Employees (FY)
350
Change (1Y)
−23 −6.17%
Revenue / Employee (1Y)
‪2.80 M‬ EUR
Net income / Employee (1Y)
‪1.23 M‬ EUR

About Halozyme Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Helen I. Torley
Website
halozyme.com
Headquarters
San Diego
Founded
1998
FIGI
BBG01TNY07L6
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1HALO news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

1HALO highest yielding bonds


HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027
Yield to maturity
−2.21%
Maturity date
Mar 1, 2027
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028
Yield to maturity
−4.66%
Maturity date
Aug 15, 2028

See all 1HALO bonds 

Sparks


Curated watchlists where 1HALO is featured.

See all sparks 


Check out other big names from the same industry as 1HALO.

Frequently Asked Questions


The current price of 1HALO is 53.58 EUR — it has increased by 0.11% in the past 24 hours. Watch HALOZYME THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange HALOZYME THERAPEUTICS INC stocks are traded under the ticker 1HALO.
1HALO stock has risen by 0.22% compared to the previous week, the month change is a 0.22% rise, over the last year HALOZYME THERAPEUTICS INC has showed a 0.22% increase.
We've gathered analysts' opinions on HALOZYME THERAPEUTICS INC future price: according to them, 1HALO price has a max estimate of 69.10 EUR and a min estimate of 51.39 EUR. Watch 1HALO chart and read a more detailed HALOZYME THERAPEUTICS INC stock forecast: see what analysts think of HALOZYME THERAPEUTICS INC and suggest that you do with its stocks.
1HALO reached its all-time high on May 2, 2025 with the price of 53.58 EUR, and its all-time low was 51.52 EUR and was reached on Apr 25, 2025. View more price dynamics on 1HALO chart.
See other stocks reaching their highest and lowest prices.
1HALO stock is 0.11% volatile and has beta coefficient of 0.83. Track HALOZYME THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is HALOZYME THERAPEUTICS INC there?
Yes, you can track HALOZYME THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
HALOZYME THERAPEUTICS INC is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
1HALO earnings for the last quarter are 1.22 EUR per share, whereas the estimation was 1.12 EUR resulting in a 8.78% surprise. The estimated earnings for the next quarter are 0.85 EUR per share. See more details about HALOZYME THERAPEUTICS INC earnings.
HALOZYME THERAPEUTICS INC revenue for the last quarter amounts to ‪287.87 M‬ EUR, despite the estimated figure of ‪276.02 M‬ EUR. In the next quarter, revenue is expected to reach ‪212.70 M‬ EUR.
1HALO net income for the last quarter is ‪132.35 M‬ EUR, while the quarter before that showed ‪123.06 M‬ EUR of net income which accounts for 7.55% change. Track more HALOZYME THERAPEUTICS INC financial stats to get the full picture.
No, 1HALO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 4, 2025, the company has 350 employees. See our rating of the largest employees — is HALOZYME THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HALOZYME THERAPEUTICS INC EBITDA is ‪611.29 M‬ EUR, and current EBITDA margin is 62.32%. See more stats in HALOZYME THERAPEUTICS INC financial statements.
Like other stocks, 1HALO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HALOZYME THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.